CytoSorbents Corporation (CTSO)

[woodstock135]

Cytosorbents Corp (NASDAQ:CTSO) Director Al Kraus unloaded 100,000 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $0.27, for a total value of $27,000.00. Following the sale, the director now directly owns 1,393,631 shares of the company’s stock, valued at approximately $376,280. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Cytosorbents Corp (NASDAQ:CTSO) opened at 0.27 on Thursday. Cytosorbents Corp has a one year low of $0.09 and a one year high of $0.35. The stock has a 50-day moving average of $0.25 and a 200-day moving average of $0.24. The company’s market cap is $80.7 million.

Cytosorbents Corp (NASDAQ:CTSO) last announced its earnings results on Tuesday, August 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). Analysts expect that Cytosorbents Corp will post $-0.03 EPS for the current fiscal year.

Separately, analysts at HC Wainwright initiated coverage on shares of Cytosorbents Corp in a research note on Monday. They set a “buy” rating and a $1.00 price target on the stock.

CytoSorbents Corporation is a development stage critical care focused company using blood purification to treat life-threatening illnesses.